Verrica Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Verrica Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 43% to $5,124,000. Profit margin reached -1307%. Total operating expenses were $70,137,000.
Profit Margin
| 2016 | 0 | -1.91M | |
|---|---|---|---|
| 2017 | 0 | -4.45M | |
| 2018 | 0 | -20.64M | |
| 2019 | 0 | -27.95M | |
| 2020 | 0 | -45.49M | |
| 2021 | 12M | -38.90M | -324.19% |
| 2022 | 9.03M | -27.67M | -306.44% |
| 2023 | 5.12M | -66.99M | -1307.47% |
VRCA Income Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue | 5.12M | 9.03M | 12M | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 746K | 725K | 472K | 229K | 257.19K | 0 | 0 | 0 |
Gross profit | 4.37M | 8.30M | 11.52M | -229K | -257.19K | 0 | 0 | 0 |
Operating exp. | ||||||||
Research and development | 20.29M | 12.19M | 15.92M | 15.67M | 15.43M | 12.82M | 3.73M | 1.70M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 70.13M | 29.60M | 42.90M | 40.18M | 30.08M | 21.87M | 4.45M | 1.91M |
Operating income | -65.75M | -21.29M | -30.90M | -40.18M | -30.08M | -21.87M | -4.45M | -1.91M |
Other income (expenses), net | -1.23M | -3.19M | -4.17M | -2.51M | 1.87M | -1K | -2K | 0 |
Income before tax | -66.99M | -24.48M | -35.08M | -42.69M | -28.20M | -20.64M | -4.45M | -1.91M |
Income tax expense | 0 | 3.19M | 3.82M | 2.80M | -257K | 1.23M | -4.45M | 0 |
Net income | -66.99M | -27.67M | -38.90M | -45.49M | -27.95M | -20.64M | -4.45M | -1.91M |
Earnings per share | ||||||||
Basic EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.09 |
Diluted EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.09 |
| Data source | Data source | Data source | Data source | Data source | Data source |